La cirrosis hepática resulta de una hepatitis crónica, y se caracteriza por fibrosis avanzada debido a la inflamación hepática a largo plazo. La cirrosis finalmente conduce a manifestaciones de ictericia., ascitis, y encefalopatía, y aumenta el riesgo de carcinoma hepatocelular. Once cirrhosis is established, resulting in hepatic failure, no effective treatment is available. Por lo tanto, novel therapies to inhibit disease progression of cirrhosis are needed.
The objective of this investigator-initiated clinical trial is to assess the safety and efficacy of autologous adipose tissue-derived regenerative (madre) cell therapy delivered to the liver via the hepatic artery in patients with liver cirrhosis.
Through consultation with the Japan Pharmaceuticals and Medical Devices Agency, we designed a clinical trial to assess a therapy for liver cirrhosis based on autologous adipose tissue-derived regenerative (madre) células, which are extracted using an adipose tissue dissociation device. The primary endpoints of the trial are the serum albumin concentration, prothrombin activity, harmful events, and device malfunction.
Enrollment and registration were initiated in November 2017, and the follow-up period ended in November 2019. Data analysis and the clinical study report will be completed by the end of March 2020.
Completion of this clinical trial, including data analysis, will provide data on the safety and efficacy of this novel liver repair therapy based on autologous adipose tissue-derived regenerative (madre) cells using an adipose tissue dissociation device.